Analysis of small cell lung cancer (SCLC) patients (Pts) treated on cancer therapy evaluation program (CTEP)-sponsored phase I trials: 1992-2012.

被引：0
|
作者：
Forde, Patrick M.
Hooker, Craig M.
Rubinstein, Larry
Hann, Christine L.
Harris, Pamela Jo
机构：
[1] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA
[2] Biometr Res Branch, Bethesda, MD USA
[3] NCI, Bethesda, MD 20892 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.7524
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7524
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Doxorubicin and Topotecan for Relapsed/Refractory Small Cell Lung Cancer (SCLC): A FPBCC Clinical Trials Network Phase I Study
    Umakanthan, J. Manikkam
    Marr, A.
    Ernani, V.
    Kessinger, M.
    Smith, L.
    Tijerina, J.
    Radniecki, S.
    Kosmacek, E.
    Ketcham, M.
    Ganti, A. K.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2188 - S2188
  • [32] A phase I study of cisplatin, etoposide, and paclitaxel (PET) in small cell lung cancer (SCLC)
    Kelly, K
    Wood, ME
    Bunn, PA
    SEMINARS IN ONCOLOGY, 1999, 26 (06) : 20 - 20
  • [33] Phase I study of weekly topotecan (T) in recurrent small cell lung cancer (SCLC)
    Groteluschen, D
    Traynor, A
    Schiller, J
    Dubey, S
    Hoang, T
    Kim, K
    Hansen, R
    Kwong, R
    Hammes, L
    Liverseed, K
    LUNG CANCER, 2005, 49 : S320 - S320
  • [34] Phase I study of ramucirumab in combination with irinotecan plus cisplatin in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC)
    Takahashi, T.
    Mori, K.
    Mizuno, R.
    Mamesaya, N.
    Kobayashi, H.
    Omori, S.
    Wakuda, K.
    Ono, A.
    Naito, T.
    Murakami, H.
    Kenmotsu, H.
    ANNALS OF ONCOLOGY, 2021, 32 : S1165 - S1165
  • [35] Pooled analysis of topotecan (T) in the second-line treatment of patients (pts) with sensitive small cell lung cancer (SCLC)
    Eckardt, J
    Depierre, A
    Ardizzoni, A
    VonPawel, J
    Fields, S
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 1041 - 1041
  • [36] A Retrospective Review of Small Cell Lung Cancer (SCLC) Patients Treated at Marmara University Hospital
    Eris, A.
    Ozturk, M.
    Dane, F.
    Bozkurtlar, E.
    Kocakaya, D.
    Alan, O.
    Hasanov, R.
    Telli, T.
    Halil, S.
    Tanrikulu, E.
    Yumuk, P.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2340 - S2340
  • [37] Phase II study of maintenance pembrolizumab (pembro) in extensive stage small cell lung cancer (ES-SCLC) patients (pts).
    Gadgeel, Shirish M.
    Ventimiglia, Jaclyn
    Kalemkerian, Gregory Peter
    Fidler, Mary J.
    Chen, Wei
    Sukari, Ammar
    Halmos, Balazs
    Boerner, Julie
    Wozniak, Antoinette J.
    Galasso, Cathy
    Pennell, Nathan A.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [38] Pemetrexed in patients (pts) with relapsed small cell lung cancer (SCLC): A phase II study from the Hoosier Oncology Group.
    Hanna, N. H.
    Ansari, R.
    Bhatia, S.
    Govindan, R.
    Bruetman, D.
    Hosford, M.
    Fisher, W.
    White, A.
    Breen, T.
    Juliar, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 379S - 379S
  • [39] Gemcitabine and etoposide in small cell lung cancer: Phase I and II trials
    Rassmann, I
    Thodtmann, R
    Depenbrock, H
    Blatter, J
    Gatzemeier, U
    Rastetter, J
    Hanauske, AR
    SEMINARS IN ONCOLOGY, 1997, 24 (02) : S75 - S78
  • [40] PROGNOSTIC FACTORS FOR SURVIVAL IN PATIENTS (PTS) WITH SMALL CELL LUNG CANCER (SCLC): VALIDATION STUDY OF A PUBLISHED CLASSIFICATION
    Paesmans, M.
    Lafitte, J. J.
    Lecomte, J.
    Berghmans, T.
    Efremidis, A.
    Meert, A. P.
    Leclercq, N.
    Sculier, J.
    LUNG CANCER, 2009, 64 : S61 - S61
12345